Renalytix (RENXF)

OTHER OTC:RENXF

RENXF

Renalytix

RESEARCH TOOLSreports

Renalytix (RENXF) Price & Analysis

8 Followers

RENXF Stock Chart & Stats

$0.08

Market closed

$0.08

Day’s Range― - ―

52-Week Range$0.02 - $0.18

Previous CloseN/A

VolumeN/A

Average Volume (3M)35.00

Market Cap

$10.56M

Enterprise Value$26.40M

Total Cash (Recent Filing)$9.63M

Total Debt (Recent Filing)$8.21M

Price to Earnings (P/E)―

Beta0.41

Next Earnings

Nov 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding437,018,680

10 Day Avg. Volume0

30 Day Avg. Volume35

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-1.38

Price to Sales (P/S)3.23

P/FCF Ratio-0.54

Enterprise Value/Market Cap2.50

Enterprise Value/Revenue11.13

Enterprise Value/Gross Profit56.42

Enterprise Value/Ebitda-1.14

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

AI-enabled Diagnostics & CKD FocusRenalytix’s focus on AI-driven biomarker diagnostics for CKD targets a persistent clinical need: earlier risk stratification. Structural trends—aging populations, rising diabetes/CKD prevalence, and demand for predictive tools—create multi-year adoption tailwinds if clinical utility and reimbursement hold.

Improving Revenue And Gross MarginA 26% revenue increase and a sharp gross margin improvement indicate improving unit economics and early product-market traction. If margin expansion persists with scale, the business model can move toward positive operating leverage as fixed costs are spread across higher test volumes.

Scalable Test-per-service Commercial ModelA per-test revenue model tied to reimbursement and health-system contracts is inherently scalable: increased adoption translates directly to recurring revenue. Strategic partnerships and adoption in care pathways can accelerate volume growth and create predictable revenue streams if reimbursement is secured.

Bears Say

Negative Equity And Stressed Balance SheetNegative equity signals a weakened capital structure and limits financial flexibility. The company is likely to rely on dilutive financing or restructuring to fund operations, which raises governance and execution risk and constrains the ability to invest opportunistically or absorb adverse shocks.

Sustained Heavy Cash BurnPersistent negative operating and free cash flow (~-17.9m) requires ongoing financing and creates execution risk. Continued cash burn reduces runway for commercialization and R&D, increases fundraising frequency, and can force suboptimal strategic choices or slow adoption initiatives.

Very Small Revenue Base Vs Large Net LossesWith revenues still tiny relative to operating costs, the company remains far from break-even. Large negative margins highlight high fixed costs and limited scaling to date; achieving sustainable profitability requires substantial and sustained growth in test volumes and reimbursement rates.

Renalytix News

Renalytix boosts kidneyintelX.dkd capacity and advances CE marking for European push

An announcement from Renalytix ( ($GB:RENX) ) is now available. Renalytix has completed the transfer of its laboratory...

1M ago

Renalytix Grows Revenue and Integration Footprint as It Pursues National Rollout of KidneyintelX.dkd

Renalytix ( ($GB:RENX) ) has issued an announcement. Renalytix reported first-half FY26 revenues of $1.6 million, up from...

2M ago

Renalytix Lifts Revenue as KidneyintelX Expansion and Distribution Talks Gather Pace

Renalytix ( ($GB:RENX) ) has shared an update. Renalytix reported first-half fiscal 2026 revenues of $1.6 million, up...

2M ago

Renalytix CEO Boosts Stake as Kidney Disease Test Rollout Advances

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix said Chief Executive James McCullough has increased his stake...

4M ago

Renalytix CFO Increases Stake as KidneyintelX.dkd Deployment Expands

Renalytix ( ($GB:RENX) ) just unveiled an update. Renalytix plc reported that interim Chief Financial Officer Joel Jung...

4M ago

Renalytix CFO Increases Stake as Kidney Disease Test Gains Traction

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix announced that interim Chief Financial Officer Joel Jung purchased...

4M ago

Renalytix CEO Increases Stake Amid Expansion of Kidney Disease Test

Renalytix ( ($GB:RENX) ) just unveiled an update. Renalytix plc announced that Chief Executive Officer James McCullough purchased...

4M ago

Renalytix Eyes Revenue Growth as Kidney Diagnostic Expands U.S. Footprint

The latest announcement is out from Renalytix ( ($GB:RENX) ). Renalytix reported unaudited first-half fiscal 2026 revenues of...

4M ago

Renalytix Adds Three U.S. Kidney Care Integrations and Deepens Tempus AI Collaboration

Renalytix ( ($GB:RENX) ) has shared an announcement. Renalytix has expanded the clinical footprint of its kidneyintelX.dkd test...

5M ago

Renalytix Secures Shareholder Support at AGM and Advances Kidney Disease Diagnostics

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix announced that all resolutions were passed at its Annual...

6M ago

RENXF FAQ

What was Renalytix’s price range in the past 12 months?

Renalytix lowest stock price was $0.02 and its highest was $0.18 in the past 12 months.

What is Renalytix’s market cap?

Renalytix’s market cap is $10.56M.

When is Renalytix’s upcoming earnings report date?

Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 152 days.

How were Renalytix’s earnings last quarter?

Renalytix released its earnings results on Mar 26, 2026. The company reported -$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.021.

Is Renalytix overvalued?

According to Wall Street analysts Renalytix’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renalytix pay dividends?

Renalytix does not currently pay dividends.

What is Renalytix’s EPS estimate?

Renalytix’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renalytix have?

Renalytix has 437,018,680 shares outstanding.

What happened to Renalytix’s price movement after its last earnings report?

Renalytix reported an EPS of -$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Renalytix?

Currently, no hedge funds are holding shares in RENXF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.